Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Gynecologic 3Lymphoid 2Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
chiauranib × Lymphoid × Clear all
NCT03974243 2022-03-09

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
9 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03074825 2019-07-24

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1 Terminated
5 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡